View ValuationInnospec 향후 성장Future 기준 점검 3/6Innospec은 연간 수입과 매출이 각각 14.8%와 7.1% 증가할 것으로 예상되고 EPS는 연간 14.9%만큼 증가할 것으로 예상됩니다.핵심 정보14.8%이익 성장률14.86%EPS 성장률Chemicals 이익 성장40.4%매출 성장률7.1%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트12 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 10Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2026, Payable on May 29, 2026Innospec Inc. declared its semi-annual dividend of 92 cents per common share for the first half of 2026, representing an increase of 10%. This dividend will be paid on May 29, 2026 to shareholders of record on May 19, 2026.공시 • May 08Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $75 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $75 million worth of its common stock.Reported Earnings • May 08First quarter 2026 earnings released: EPS: US$1.23 (vs US$1.31 in 1Q 2025)First quarter 2026 results: EPS: US$1.23 (down from US$1.31 in 1Q 2025). Revenue: US$453.2m (up 2.8% from 1Q 2025). Net income: US$30.4m (down 7.3% from 1Q 2025). Profit margin: 6.7% (down from 7.4% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 7.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.공시 • Apr 08Innospec Inc. to Report Q1, 2026 Results on May 07, 2026Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026공시 • Mar 27Innospec Inc., Annual General Meeting, May 08, 2026Innospec Inc., Annual General Meeting, May 08, 2026. Location: the st. regis new york, two east 55th street, at fifth avenue, usa 10022, new york United StatesReported Earnings • Feb 18Full year 2025 earnings released: EPS: US$4.69 (vs US$1.43 in FY 2024)Full year 2025 results: EPS: US$4.69 (up from US$1.43 in FY 2024). Revenue: US$1.78b (down 3.7% from FY 2024). Net income: US$116.6m (up 228% from FY 2024). Profit margin: 6.6% (up from 1.9% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 2 years, compared to a 13% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.공시 • Jan 12Innospec Inc. to Report Q4, 2025 Results on Feb 17, 2026Innospec Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026Board Change • Jan 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Declared Dividend • Nov 08Dividend of US$0.87 announcedShareholders will receive a dividend of US$0.87. Ex-date: 18th November 2025 Payment date: 26th November 2025 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.52 (vs US$1.34 in 3Q 2024)Third quarter 2025 results: EPS: US$0.52 (down from US$1.34 in 3Q 2024). Revenue: US$441.9m (flat on 3Q 2024). Net income: US$12.9m (down 61% from 3Q 2024). Profit margin: 2.9% (down from 7.5% in 3Q 2024). Revenue is forecast to grow 5.7% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.공시 • Nov 05Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2025, Payable on November 26, 2025Innospec Inc. declared a semi-annual dividend of 87 cents per common share for the second half of 2025, which will be paid on November 26, 2025 to shareholders of record as of November 18, 2025.Board Change • Oct 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Oct 02Innospec Inc. to Report Q3, 2025 Results on Nov 04, 2025Innospec Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025Board Change • Sep 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 06Second quarter 2025 earnings released: EPS: US$0.94 (vs US$1.25 in 2Q 2024)Second quarter 2025 results: EPS: US$0.94 (down from US$1.25 in 2Q 2024). Revenue: US$439.7m (up 1.1% from 2Q 2024). Net income: US$23.5m (down 25% from 2Q 2024). Profit margin: 5.3% (down from 7.2% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.공시 • Jul 03Innospec Inc. to Report Q2, 2025 Results on Aug 05, 2025Innospec Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025Board Change • Jun 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Declared Dividend • May 19Dividend of US$0.84 announcedShareholders will receive a dividend of US$0.84. Ex-date: 20th May 2025 Payment date: 30th May 2025 Dividend yield will be 1.8%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is not covered by earnings (143% earnings payout ratio). However, it is covered by cash flows (57% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 59% to bring the payout ratio under control. EPS is expected to grow by 65% over the next year, which is sufficient to bring the dividend into a sustainable range.Board Change • May 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • May 09Innospec Inc. Declares Semi-Annual Dividend, Payable on May 30, 2025Innospec Inc. declared its semi-annual dividend of 84 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 30, 2025 to shareholders of record on May 20, 2025.Buy Or Sell Opportunity • Apr 10Now 24% overvaluedThe stock has been flat over the last 90 days, currently trading at US$85.47. The fair value is estimated to be US$68.79, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 10.0% in 2 years. Earnings are forecast to grow by 345% in the next 2 years.공시 • Apr 04Innospec Inc. to Report Q1, 2025 Results on May 08, 2025Innospec Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025공시 • Mar 28Innospec Inc., Annual General Meeting, May 09, 2025Innospec Inc., Annual General Meeting, May 09, 2025. Location: westin at the woodlands hotel, 2 waterway square place, the woodlands, houston tx 77380, United StatesBoard Change • Mar 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Mar 11Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $50 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock.Recent Insider Transactions • Mar 09Executive VP & CFO recently sold US$432k worth of stockOn the 3rd of March, Ian Cleminson sold around 4k shares on-market at roughly US$101 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by US$1.6m.Recent Insider Transactions • Feb 26COO & Executive VP recently sold US$388k worth of stockOn the 21st of February, Philip Boon sold around 4k shares on-market at roughly US$103 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Philip's only on-market trade for the last 12 months.New Risk • Feb 19New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 7.2% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.9% net profit margin).Reported Earnings • Feb 19Full year 2024 earnings released: EPS: US$1.43 (vs US$5.60 in FY 2023)Full year 2024 results: EPS: US$1.43 (down from US$5.60 in FY 2023). Revenue: US$1.85b (down 5.3% from FY 2023). Net income: US$35.6m (down 74% from FY 2023). Profit margin: 1.9% (down from 7.1% in FY 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 2 years, compared to a 4.0% decline forecast for the Chemicals industry in the United Kingdom.Board Change • Jan 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.공시 • Jan 09Innospec Inc. to Report Q4, 2024 Results on Feb 18, 2025Innospec Inc. announced that they will report Q4, 2024 results After-Market on Feb 18, 2025Declared Dividend • Nov 11Dividend of US$0.79 announcedShareholders will receive a dividend of US$0.79. Ex-date: 18th November 2024 Payment date: 26th November 2024 Dividend yield will be 1.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 2 years, which should provide support to the dividend and adequate earnings cover.New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Significant insider selling over the past 3 months (US$1.1m sold).Reported Earnings • Nov 06Third quarter 2024 earnings released: EPS: US$1.34 (vs US$1.58 in 3Q 2023)Third quarter 2024 results: EPS: US$1.34 (down from US$1.58 in 3Q 2023). Revenue: US$443.4m (down 4.5% from 3Q 2023). Net income: US$33.4m (down 15% from 3Q 2023). Profit margin: 7.5% (down from 8.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.8% p.a. on average during the next 2 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.공시 • Oct 04Innospec Inc. to Report Q3, 2024 Results on Nov 06, 2024Innospec Inc. announced that they will report Q3, 2024 results on Nov 06, 2024Recent Insider Transactions • Aug 29Executive VP & CFO recently sold US$1.1m worth of stockOn the 26th of August, Ian Cleminson sold around 10k shares on-market at roughly US$114 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by US$1.7m.Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: US$1.25 (vs US$1.16 in 2Q 2023)Second quarter 2024 results: EPS: US$1.25 (up from US$1.16 in 2Q 2023). Revenue: US$435.0m (down 9.5% from 2Q 2023). Net income: US$31.2m (up 8.0% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Buy Or Sell Opportunity • Jul 17Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 9.2% to US$132. The fair value is estimated to be US$107, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 4.0% in a year. Earnings are forecast to grow by 11% in the next year.공시 • Jul 04Innospec Inc. to Report Q2, 2024 Results on Aug 06, 2024Innospec Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024공시 • May 11Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2024Innospec Inc. declared its semi-annual dividend of 76 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 31, 2024 to shareholders of record on May 20, 2024.Reported Earnings • May 10First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.34 in 1Q 2023)First quarter 2024 results: EPS: US$1.66 (up from US$1.34 in 1Q 2023). Revenue: US$500.2m (down 1.8% from 1Q 2023). Net income: US$41.4m (up 25% from 1Q 2023). Profit margin: 8.3% (up from 6.5% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom.공시 • Apr 06Innospec Inc. to Report Q1, 2024 Results on May 09, 2024Innospec Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024공시 • Apr 03Innospec Inc. Announces Retirement of Philip Boon, Executive Vice President and Chief Operating Officer Effective March 31, 2025On March 31, 2024, Dr. Philip Boon, Executive Vice President and Chief Operating Officer of Innospec Inc. (the “Company”), informed the Company of his decision to officially retire effective March 31, 2025. Dr. Boon will provide various support to the Company on a consultancy basis, on terms to be agreed, after his retirement.공시 • Mar 29Innospec Inc., Annual General Meeting, May 10, 2024Innospec Inc., Annual General Meeting, May 10, 2024, at 10:00 US Eastern Standard Time. Location: The offices of Smith, Gambrell & Russell LLP 1105 West Peachtree Street NE suite 1000 Atlanta Georgia United States Agenda: To consider election of two Class II Directors; to consider advisory approval of the Company’s executive compensation; to consider ratification of the appointment of the Company’s independent registered public accounting firm; and to discuss other matters.Recent Insider Transactions • Feb 28President recently sold US$1.2m worth of stockOn the 23rd of February, Patrick Williams sold around 10k shares on-market at roughly US$124 per share. This transaction amounted to 5.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Patrick has been a net seller over the last 12 months, reducing personal holdings by US$4.3m.Reported Earnings • Feb 14Full year 2023 earnings released: EPS: US$5.60 (vs US$5.37 in FY 2022)Full year 2023 results: EPS: US$5.60 (up from US$5.37 in FY 2022). Revenue: US$1.95b (flat on FY 2022). Net income: US$139.1m (up 4.6% from FY 2022). Profit margin: 7.1% (up from 6.8% in FY 2022). Revenue is forecast to grow 1.5% p.a. on average during the next 2 years, compared to a 4.4% decline forecast for the Chemicals industry in the United Kingdom.Board Change • Dec 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Dec 12Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A.Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A. on December 8, 2023. Innospec will integrate QGP into its Performance Chemicals business. Innospec Inc. (NasdaqGS:IOSP) completed the acquisition of QGP Química Geral S.A. on December 8, 2023.Board Change • Dec 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 10Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.56 in 3Q 2022)Third quarter 2023 results: EPS: US$1.58 (up from US$1.56 in 3Q 2022). Revenue: US$464.1m (down 9.5% from 3Q 2022). Net income: US$39.2m (up 1.3% from 3Q 2022). Profit margin: 8.4% (up from 7.5% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.공시 • Nov 08Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2023, Payable on November 27, 2023Innospec Inc. announced that it has declared a semi-annual dividend of 72 cents per common share for the second half of 2023 which will be paid on November 27, 2023 to shareholders of record as of November 20, 2023. This brings the annual dividend to $1.41 per share, a 10 percent increase over 2022.공시 • Aug 13Innospec Inc. to Report Q3, 2023 Results on Nov 07, 2023Innospec Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 07, 2023공시 • Jul 07Innospec Inc. to Report Q2, 2023 Results on Aug 08, 2023Innospec Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2023Upcoming Dividend • May 12Upcoming dividend of US$0.69 per share at 1.4% yieldEligible shareholders must have bought the stock before 19 May 2023. Payment date: 31 May 2023. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.3%).Reported Earnings • May 05First quarter 2023 earnings released: EPS: US$1.34 (vs US$1.47 in 1Q 2022)First quarter 2023 results: EPS: US$1.34 (down from US$1.47 in 1Q 2022). Revenue: US$509.6m (up 7.9% from 1Q 2022). Net income: US$33.2m (down 9.0% from 1Q 2022). Profit margin: 6.5% (down from 7.7% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.3% p.a. on average during the next 2 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom.공시 • May 05Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2023Innospec Inc. declared a semi-annual dividend of $0.69 per share on the Company’s common stock (IOSP). The dividend will be paid on May 31, 2023 to holders of record on May 22, 2023.Recent Insider Transactions • Mar 04President recently sold US$2.0m worth of stockOn the 28th of February, Patrick Williams sold around 18k shares on-market at roughly US$111 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months.Reported Earnings • Feb 23Full year 2022 earnings released: EPS: US$5.37 (vs US$3.78 in FY 2021)Full year 2022 results: EPS: US$5.37 (up from US$3.78 in FY 2021). Revenue: US$1.96b (up 32% from FY 2021). Net income: US$133.0m (up 43% from FY 2021). Profit margin: 6.8% (up from 6.3% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom.공시 • Jan 11Innospec Inc. to Report Q4, 2022 Results on Feb 21, 2023Innospec Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 21, 2023이익 및 매출 성장 예측LSE:0JAX - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20272,02614789153212/31/20261,8731216913733/31/20261,79011454128N/A12/31/20251,77811763138N/A9/30/20251,789-128103N/A6/30/20251,7911972137N/A3/31/20251,7862769132N/A12/31/20241,84536122185N/A9/30/20241,873144169231N/A6/30/20241,894150148216N/A3/31/20241,939147197266N/A12/31/20231,949139130207N/A9/30/20231,965127142213N/A6/30/20232,014126131195N/A3/31/20232,00113077133N/A12/31/20221,9641333982N/A9/30/20221,8661313372N/A6/30/20221,729116-235N/A3/31/20221,616106442N/A12/31/20211,483935493N/A9/30/20211,381924783N/A6/30/20211,27081101135N/A3/31/20211,16019134166N/A12/31/20201,19329116146N/A9/30/20201,27337117146N/A6/30/20201,38055102131N/A3/31/20201,497117123151N/A12/31/20191,513112N/A162N/A9/30/20191,518102N/A173N/A6/30/20191,50992N/A168N/A3/31/20191,50592N/A120N/A12/31/20181,47785N/A105N/A9/30/20181,43660N/A83N/A6/30/20181,40563N/A94N/A3/31/20181,37367N/A101N/A12/31/20171,30762N/A83N/A9/30/20171,19189N/A54N/A6/30/20171,06477N/A38N/A3/31/201796680N/A79N/A12/31/201688381N/A106N/A9/30/201689291N/A114N/A6/30/2016940115N/A120N/A3/31/2016955121N/A106N/A12/31/20151,012120N/A118N/A9/30/20151,057116N/A138N/A6/30/20151,031101N/A128N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 0JAX 의 연간 예상 수익 증가율(14.8%)이 saving rate(3.4%)보다 높습니다.수익 vs 시장: 0JAX 의 연간 수익(14.8%)이 UK 시장(11.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 0JAX 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 0JAX 의 수익(연간 7.1%)이 UK 시장(연간 4.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 0JAX 의 수익(연간 7.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 0JAX의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/16 04:19종가2026/05/15 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Innospec Inc.는 7명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jonathan TanwantengCJS Securities, Inc.David SilverFreedom Capital MarketsSean MilliganJohnson Rice & Company, L.L.C.4명의 분석가 더 보기
공시 • May 10Innospec Inc. Declares Semi-Annual Dividend for the First Half of 2026, Payable on May 29, 2026Innospec Inc. declared its semi-annual dividend of 92 cents per common share for the first half of 2026, representing an increase of 10%. This dividend will be paid on May 29, 2026 to shareholders of record on May 19, 2026.
공시 • May 08Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $75 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $75 million worth of its common stock.
Reported Earnings • May 08First quarter 2026 earnings released: EPS: US$1.23 (vs US$1.31 in 1Q 2025)First quarter 2026 results: EPS: US$1.23 (down from US$1.31 in 1Q 2025). Revenue: US$453.2m (up 2.8% from 1Q 2025). Net income: US$30.4m (down 7.3% from 1Q 2025). Profit margin: 6.7% (down from 7.4% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 2 years, compared to a 7.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
공시 • Apr 08Innospec Inc. to Report Q1, 2026 Results on May 07, 2026Innospec Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 07, 2026
공시 • Mar 27Innospec Inc., Annual General Meeting, May 08, 2026Innospec Inc., Annual General Meeting, May 08, 2026. Location: the st. regis new york, two east 55th street, at fifth avenue, usa 10022, new york United States
Reported Earnings • Feb 18Full year 2025 earnings released: EPS: US$4.69 (vs US$1.43 in FY 2024)Full year 2025 results: EPS: US$4.69 (up from US$1.43 in FY 2024). Revenue: US$1.78b (down 3.7% from FY 2024). Net income: US$116.6m (up 228% from FY 2024). Profit margin: 6.6% (up from 1.9% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 2 years, compared to a 13% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
공시 • Jan 12Innospec Inc. to Report Q4, 2025 Results on Feb 17, 2026Innospec Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026
Board Change • Jan 05Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Declared Dividend • Nov 08Dividend of US$0.87 announcedShareholders will receive a dividend of US$0.87. Ex-date: 18th November 2025 Payment date: 26th November 2025 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 12% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability.
Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.52 (vs US$1.34 in 3Q 2024)Third quarter 2025 results: EPS: US$0.52 (down from US$1.34 in 3Q 2024). Revenue: US$441.9m (flat on 3Q 2024). Net income: US$12.9m (down 61% from 3Q 2024). Profit margin: 2.9% (down from 7.5% in 3Q 2024). Revenue is forecast to grow 5.7% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
공시 • Nov 05Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2025, Payable on November 26, 2025Innospec Inc. declared a semi-annual dividend of 87 cents per common share for the second half of 2025, which will be paid on November 26, 2025 to shareholders of record as of November 18, 2025.
Board Change • Oct 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 02Innospec Inc. to Report Q3, 2025 Results on Nov 04, 2025Innospec Inc. announced that they will report Q3, 2025 results After-Market on Nov 04, 2025
Board Change • Sep 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 06Second quarter 2025 earnings released: EPS: US$0.94 (vs US$1.25 in 2Q 2024)Second quarter 2025 results: EPS: US$0.94 (down from US$1.25 in 2Q 2024). Revenue: US$439.7m (up 1.1% from 2Q 2024). Net income: US$23.5m (down 25% from 2Q 2024). Profit margin: 5.3% (down from 7.2% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 2 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.
공시 • Jul 03Innospec Inc. to Report Q2, 2025 Results on Aug 05, 2025Innospec Inc. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025
Board Change • Jun 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Declared Dividend • May 19Dividend of US$0.84 announcedShareholders will receive a dividend of US$0.84. Ex-date: 20th May 2025 Payment date: 30th May 2025 Dividend yield will be 1.8%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is not covered by earnings (143% earnings payout ratio). However, it is covered by cash flows (57% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to grow by 59% to bring the payout ratio under control. EPS is expected to grow by 65% over the next year, which is sufficient to bring the dividend into a sustainable range.
Board Change • May 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • May 09Innospec Inc. Declares Semi-Annual Dividend, Payable on May 30, 2025Innospec Inc. declared its semi-annual dividend of 84 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 30, 2025 to shareholders of record on May 20, 2025.
Buy Or Sell Opportunity • Apr 10Now 24% overvaluedThe stock has been flat over the last 90 days, currently trading at US$85.47. The fair value is estimated to be US$68.79, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 10.0% in 2 years. Earnings are forecast to grow by 345% in the next 2 years.
공시 • Apr 04Innospec Inc. to Report Q1, 2025 Results on May 08, 2025Innospec Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025
공시 • Mar 28Innospec Inc., Annual General Meeting, May 09, 2025Innospec Inc., Annual General Meeting, May 09, 2025. Location: westin at the woodlands hotel, 2 waterway square place, the woodlands, houston tx 77380, United States
Board Change • Mar 26Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Mar 11Innospec Inc. (NasdaqGS:IOSP) announces an Equity Buyback for $50 million worth of its shares.Innospec Inc. (NasdaqGS:IOSP) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of its common stock.
Recent Insider Transactions • Mar 09Executive VP & CFO recently sold US$432k worth of stockOn the 3rd of March, Ian Cleminson sold around 4k shares on-market at roughly US$101 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by US$1.6m.
Recent Insider Transactions • Feb 26COO & Executive VP recently sold US$388k worth of stockOn the 21st of February, Philip Boon sold around 4k shares on-market at roughly US$103 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Philip's only on-market trade for the last 12 months.
New Risk • Feb 19New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 7.2% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.9% net profit margin).
Reported Earnings • Feb 19Full year 2024 earnings released: EPS: US$1.43 (vs US$5.60 in FY 2023)Full year 2024 results: EPS: US$1.43 (down from US$5.60 in FY 2023). Revenue: US$1.85b (down 5.3% from FY 2023). Net income: US$35.6m (down 74% from FY 2023). Profit margin: 1.9% (down from 7.1% in FY 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 2 years, compared to a 4.0% decline forecast for the Chemicals industry in the United Kingdom.
Board Change • Jan 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
공시 • Jan 09Innospec Inc. to Report Q4, 2024 Results on Feb 18, 2025Innospec Inc. announced that they will report Q4, 2024 results After-Market on Feb 18, 2025
Declared Dividend • Nov 11Dividend of US$0.79 announcedShareholders will receive a dividend of US$0.79. Ex-date: 18th November 2024 Payment date: 26th November 2024 Dividend yield will be 1.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 11% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Significant insider selling over the past 3 months (US$1.1m sold).
Reported Earnings • Nov 06Third quarter 2024 earnings released: EPS: US$1.34 (vs US$1.58 in 3Q 2023)Third quarter 2024 results: EPS: US$1.34 (down from US$1.58 in 3Q 2023). Revenue: US$443.4m (down 4.5% from 3Q 2023). Net income: US$33.4m (down 15% from 3Q 2023). Profit margin: 7.5% (down from 8.4% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.8% p.a. on average during the next 2 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 10% per year.
공시 • Oct 04Innospec Inc. to Report Q3, 2024 Results on Nov 06, 2024Innospec Inc. announced that they will report Q3, 2024 results on Nov 06, 2024
Recent Insider Transactions • Aug 29Executive VP & CFO recently sold US$1.1m worth of stockOn the 26th of August, Ian Cleminson sold around 10k shares on-market at roughly US$114 per share. This transaction amounted to 49% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ian has been a net seller over the last 12 months, reducing personal holdings by US$1.7m.
Reported Earnings • Aug 07Second quarter 2024 earnings released: EPS: US$1.25 (vs US$1.16 in 2Q 2023)Second quarter 2024 results: EPS: US$1.25 (up from US$1.16 in 2Q 2023). Revenue: US$435.0m (down 9.5% from 2Q 2023). Net income: US$31.2m (up 8.0% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 6.1% p.a. on average during the next 2 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Buy Or Sell Opportunity • Jul 17Now 24% overvalued after recent price riseOver the last 90 days, the stock has risen 9.2% to US$132. The fair value is estimated to be US$107, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 4.0% in a year. Earnings are forecast to grow by 11% in the next year.
공시 • Jul 04Innospec Inc. to Report Q2, 2024 Results on Aug 06, 2024Innospec Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024
공시 • May 11Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2024Innospec Inc. declared its semi-annual dividend of 76 cents per common share for the first half of this year, representing an increase of 10%. This dividend will be paid on May 31, 2024 to shareholders of record on May 20, 2024.
Reported Earnings • May 10First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.34 in 1Q 2023)First quarter 2024 results: EPS: US$1.66 (up from US$1.34 in 1Q 2023). Revenue: US$500.2m (down 1.8% from 1Q 2023). Net income: US$41.4m (up 25% from 1Q 2023). Profit margin: 8.3% (up from 6.5% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom.
공시 • Apr 06Innospec Inc. to Report Q1, 2024 Results on May 09, 2024Innospec Inc. announced that they will report Q1, 2024 results After-Market on May 09, 2024
공시 • Apr 03Innospec Inc. Announces Retirement of Philip Boon, Executive Vice President and Chief Operating Officer Effective March 31, 2025On March 31, 2024, Dr. Philip Boon, Executive Vice President and Chief Operating Officer of Innospec Inc. (the “Company”), informed the Company of his decision to officially retire effective March 31, 2025. Dr. Boon will provide various support to the Company on a consultancy basis, on terms to be agreed, after his retirement.
공시 • Mar 29Innospec Inc., Annual General Meeting, May 10, 2024Innospec Inc., Annual General Meeting, May 10, 2024, at 10:00 US Eastern Standard Time. Location: The offices of Smith, Gambrell & Russell LLP 1105 West Peachtree Street NE suite 1000 Atlanta Georgia United States Agenda: To consider election of two Class II Directors; to consider advisory approval of the Company’s executive compensation; to consider ratification of the appointment of the Company’s independent registered public accounting firm; and to discuss other matters.
Recent Insider Transactions • Feb 28President recently sold US$1.2m worth of stockOn the 23rd of February, Patrick Williams sold around 10k shares on-market at roughly US$124 per share. This transaction amounted to 5.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Patrick has been a net seller over the last 12 months, reducing personal holdings by US$4.3m.
Reported Earnings • Feb 14Full year 2023 earnings released: EPS: US$5.60 (vs US$5.37 in FY 2022)Full year 2023 results: EPS: US$5.60 (up from US$5.37 in FY 2022). Revenue: US$1.95b (flat on FY 2022). Net income: US$139.1m (up 4.6% from FY 2022). Profit margin: 7.1% (up from 6.8% in FY 2022). Revenue is forecast to grow 1.5% p.a. on average during the next 2 years, compared to a 4.4% decline forecast for the Chemicals industry in the United Kingdom.
Board Change • Dec 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Dec 12Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A.Innospec Inc. (NasdaqGS:IOSP) acquired QGP Química Geral S.A. on December 8, 2023. Innospec will integrate QGP into its Performance Chemicals business. Innospec Inc. (NasdaqGS:IOSP) completed the acquisition of QGP Química Geral S.A. on December 8, 2023.
Board Change • Dec 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Les Parrette was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 10Third quarter 2023 earnings released: EPS: US$1.58 (vs US$1.56 in 3Q 2022)Third quarter 2023 results: EPS: US$1.58 (up from US$1.56 in 3Q 2022). Revenue: US$464.1m (down 9.5% from 3Q 2022). Net income: US$39.2m (up 1.3% from 3Q 2022). Profit margin: 8.4% (up from 7.5% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth.
공시 • Nov 08Innospec Inc. Declares Semi-Annual Dividend for the Second Half of 2023, Payable on November 27, 2023Innospec Inc. announced that it has declared a semi-annual dividend of 72 cents per common share for the second half of 2023 which will be paid on November 27, 2023 to shareholders of record as of November 20, 2023. This brings the annual dividend to $1.41 per share, a 10 percent increase over 2022.
공시 • Aug 13Innospec Inc. to Report Q3, 2023 Results on Nov 07, 2023Innospec Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Nov 07, 2023
공시 • Jul 07Innospec Inc. to Report Q2, 2023 Results on Aug 08, 2023Innospec Inc. announced that they will report Q2, 2023 results at 4:00 PM, US Eastern Standard Time on Aug 08, 2023
Upcoming Dividend • May 12Upcoming dividend of US$0.69 per share at 1.4% yieldEligible shareholders must have bought the stock before 19 May 2023. Payment date: 31 May 2023. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (2.3%).
Reported Earnings • May 05First quarter 2023 earnings released: EPS: US$1.34 (vs US$1.47 in 1Q 2022)First quarter 2023 results: EPS: US$1.34 (down from US$1.47 in 1Q 2022). Revenue: US$509.6m (up 7.9% from 1Q 2022). Net income: US$33.2m (down 9.0% from 1Q 2022). Profit margin: 6.5% (down from 7.7% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.3% p.a. on average during the next 2 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom.
공시 • May 05Innospec Inc. Declares Semi-Annual Dividend, Payable on May 31, 2023Innospec Inc. declared a semi-annual dividend of $0.69 per share on the Company’s common stock (IOSP). The dividend will be paid on May 31, 2023 to holders of record on May 22, 2023.
Recent Insider Transactions • Mar 04President recently sold US$2.0m worth of stockOn the 28th of February, Patrick Williams sold around 18k shares on-market at roughly US$111 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months.
Reported Earnings • Feb 23Full year 2022 earnings released: EPS: US$5.37 (vs US$3.78 in FY 2021)Full year 2022 results: EPS: US$5.37 (up from US$3.78 in FY 2021). Revenue: US$1.96b (up 32% from FY 2021). Net income: US$133.0m (up 43% from FY 2021). Profit margin: 6.8% (up from 6.3% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom.
공시 • Jan 11Innospec Inc. to Report Q4, 2022 Results on Feb 21, 2023Innospec Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 21, 2023